CELONOVA

Pioneers in Cardiovascular Innovation

Our Company

CeloNova BioSciences is an innovative global medical device leader led by some of the industry’s most experienced executive leaders and board members. This includes 2016 Texas Business Hall of Famer, and Executive Chairman, Dennert Ware.

Leveraging its novel Polyzene-F core technology, CeloNova is transforming the treatment of cardiovascular disease and promoting positive outcomes in patients around the world.

The proprietary COBRA PzF NanoCoated Coronary Stent System is the latest generation stent featuring the nano-thin Polyzene-F nanocoated surface modification.

In 2015, CeloNova’s interventional radiology product lines were acquired by Boston Scientific. Click here to read the press release.

Management Team

Dennert O. Ware

Executive Chairman

Mr. Ware has over 40 years of experience in the healthcare field. Most recently, he has served as the Chief Executive Officer of CeloNova from 2010 to 2014. Prior to his retirement in 2006, Mr. Ware served for 6 years as President and C.E.O. of Kinetic Concepts, Inc. where he grew revenue from approximately $350 million in 2000 to nearly $1.4 billion. Mr. Ware was named the 2005 Medical Device Executive Officer of the Year by leading industry analyst firm Frost & Sullivan in recognition of his leadership, vision and impact on KCI’s growth and performance. In addition, he was selected as a recipient of the Ernst & Young Entrepreneur of the Year award in 2006. Mr. Ware also spent 28 years with Boehringer Mannheim GmbH, acquired by F. Hoffman la Roche Ltd. in 1998, in a variety of management positions, including President and CEO of Boehringer Mannheim Corporation and Roche Diagnostics Corporation.

Mr. Ware is currently Vice Chairman of the Bexar County Performing Arts Center Foundation and a Director of the Christel House International Foundation.

Denny holds a Bachelor of Science in Chemical Engineering degree from Purdue University and an MBA from Indiana University.

Kathy Conner

Senior Vice President, Commercial Operations

Kathy Conner is the Senior Vice President, Commercial Operations for CeloNova BioSciences and is responsible for strategic marketing, sales and manufacturing of the company’s interventional cardiology business unit on a worldwide basis. Ms. Conner is a member of the CeloNova Executive Committee.

Ms. Conner is a creative, global executive with over 19 years of experience in leading strategic business planning with a proven track record of commercializing innovative products around the world, specifically in the cardiovascular segment. Prior to joining CeloNova, she was the VP, Marketing for Teleflex’s Vascular Access division where she successfully led commercialization and product portfolio planning. She has had numerous positions of increasing responsibility at Guidant, Boston Scientific, and MAQUET Cardiovascular.

Kathy earned her Bachelor of Arts degree from Kenyon College and her Masters of Business Administration from Indiana University.

Jason Cone

Senior Vice President and General Counsel

Jason Cone is the Senior Vice President and General Counsel for CeloNova BioSciences.  He is responsible for all legal matters, human resources, healthcare compliance, quality systems and regulatory affairs.  Mr. Cone serves as a member of the CeloNova Management Executive Committee.

Mr. Cone has nearly 20 years of experience as a lawyer representing a wide variety of business, healthcare and financial clients. He was a shareholder with a national law firm before joining Kinetic Concepts, Inc. (KCI), where he served as SVP, Chief Compliance Officer. In that role, Mr. Cone was responsible for global healthcare compliance, quality systems and regulatory affairs. While at KCI, he also lived and worked for two years in Amstelveen, The Netherlands, managing the company’s international legal matters. Prior to joining CeloNova, Mr. Cone held the position of General Counsel and Chief Compliance Officer for a large medical device retailer.

Mr. Cone’s education includes a Juris Doctorate with Honors from the University of Texas School of Law and a Bachelor in Business Administration from Baylor University.

Board of Directors

Dennert O. Ware

Executive Chairman

Mr. Ware has over 40 years of experience in the healthcare field. Most recently, he has served as the Chief Executive Officer of CeloNova from 2010 to 2014. Prior to his retirement in 2006, Mr. Ware served for 6 years as President and C.E.O. of Kinetic Concepts, Inc. where he grew revenue from approximately $350 million in 2000 to nearly $1.4 billion. Mr. Ware was named the 2005 Medical Device Executive Officer of the Year by leading industry analyst firm Frost & Sullivan in recognition of his leadership, vision and impact on KCI’s growth and performance. In addition, he was selected as a recipient of the Ernst & Young Entrepreneur of the Year award in 2006. Mr. Ware also spent 28 years with Boehringer Mannheim GmbH, acquired by F. Hoffman la Roche Ltd. in 1998, in a variety of management positions, including President and CEO of Boehringer Mannheim Corporation and Roche Diagnostics Corporation.

Mr. Ware is currently Vice Chairman of the Bexar County Performing Arts Center Foundation and a Director of the Christel House International Foundation.

Denny holds a Bachelor of Science in Chemical Engineering degree from Purdue University and an MBA from Indiana University.

Mark C. Bates, MD, DSC, FACC, FSCAI

Director

Dr. Bates is Director of the CAMC Cardiovascular Medicine Fellowship and Senior Scientist for Cardiovascular Research at the CAMC Research Institute. He is the Founder and Co-Director of the CAMC Vascular Center of Excellence and is Clinical Professor of Medicine and Surgery at West Virginia University School of Medicine in Charleston, WV. He is considered a thought leader in cardiovascular medicine having authored over 100 manuscripts/book chapters. Dr. Bates has performed 1000s of cardiovascular procedures and has been the site principle investigator (PI) and national PI for several US and International Clinical Trials.

Dr. Bates is also a successful entrepreneur and inventor. His passion in the field of endovascular surgery has resulted in key innovative advances with over 50 US issued / pending patents in the arenas of embolic protection, nanotechnology, stent design, cell therapy, catheter design, guide-wire design, drug eluting balloons and local drug delivery. He has been on the advisory boards of Guidant, Boston Scientific and Medtronic and has served on the Johnson & Johnson Opinion Leaders Council. He is also currently Chairman of the Board for Nexeon MedSystems, Nevada Corp.

Mark graduated from West Virginia University School of Medicine and completed his Internal Medicine residency at WVU followed by a cardiovascular fellowship at the University of Kentucky. He then was retained as a Clinical Scholar in Interventional Cardiology and Research at UK followed by a Fellowship in Vascular Medicine and Complex Vascular Intervention / Research at the Dorros-Feuer CV Research Foundation / University of Wisconsin. In 2014 Dr. Bates was honored with a Doctor of Science Degree from University of Charleston and Received the American Heart Association Heart of Gold Award in 2015.

Harry Jacobson, MD

Director

Dr. Jacobson is former Vice Chancellor for Health Affairs at Vanderbilt University and Chief Executive Officer of Vanderbilt University Medical Center (VUMC). During his more than 11 years of tenure, VUMC revenues grew from $750 million to $2.5 billion, while delivering superior care at substantially lower costs than those in similar hospitals. Its federally-funded NIH research program moved from 24th to the top 10 in the country, and over $1 billion of newly-constructed research and patient care facilities were opened during his tenure.

Dr. Jacobson has been a successful investor and entrepreneur, as well, having founded or co-founded more than ten companies, including Contact Software, Renal Care Group and Ambulatory Services of America. He has been both a formal and informal advisor to several venture and private equity funds. He formerly served on the Board of Directors of Kinetic Concepts, Inc. and Merck. Dr. Jacobson currently serves as Chairman of the Board of MedCare Investment Funds, a privately-held healthcare investment group.

Harry received his Doctor of Medicine degree from the University of Illinois in 1972 and completed his medical residency at Johns Hopkins Hospital and specialty training in nephrology at the University of Texas Health Science Center in Dallas.

Thomas (Tim) Lyles, JD

Director 

Mr. Lyles is President of Mission City Management, Inc. and MedCare Investment Funds. Mr. Lyles has managed an investment portfolio for over twenty years, including both public and large private companies. He also serves on numerous for-profit and non-profit Boards of Directors. Mr. Lyles’ primary responsibility is President of a private holding company, which oversees both strategic and operational issues for various fund portfolios. Mr. Lyles has helped organize each fund in the MedCare Investment Funds group and has served as President of each fund since 1991. As a founding partner, Mr. Lyles was an active member of management in founding Renal Care Group along with Dr. Jacobson and the late Sam Brooks. Mr. Lyles, through his role as President of MedCare Investment Funds, has founded and established numerous health care companies.

From 1984 to 1989, Mr. Lyles was an Attorney with the law firm of Haynes and Boone in Dallas, Texas. During 1986 and 1987, he taught Real Estate Financing at Southern Methodist University in Dallas. From 1983 to 1984, he was appointed a Briefing Attorney for the Chief Justice of the Supreme Court of Texas.

Tim received his Juris Doctorate Cum Laude from SMU School of Law. Prior to attending law school, he was employed by KPMG Peat Marwick. Mr. Lyles earned an accounting degree from Texas A & M University, where he graduated Summa Cum Laude. In addition, Mr. Lyles is a Certified Public Accountant and has written material for the Texas State Bar and has been a speaker for the State Bar of Texas and the Dallas Bar.

Goetz M. Richter, MD, PHD

Director

Dr. Richter is the Director of the Clinics for Diagnostic and Interventional Radiology of the Klinikum Stuttgart. Dr. Richter is a co-founder of IMED, which became CeloNova BioSciences, Inc. in October of 2005. He is widely recognized as one of the pioneers in the development of stent technology, and was one of the first physicians to place a stent in a human being. He was one of the Principal Investigators and played a key role in the development and the clinical trials of the Palmaz Stent. A noted author and lecturer, Dr. Richter is regarded as one of the leading interventional radiologists in the world.

Goetz completed his undergraduate work at the University of Stuttgart-Hohenheim and earned a Doctor of Medicine degree from University Freiberg. He is currently serving as the President of the German Society of Interventional Radiology.

Nurture your Unique Potential

At CeloNova BioSciences, you’ll have the opportunity to further your potential by joining a team of cutting edge cardiovascular innovators and leaders dedicated to transforming the treatment of coronary artery disease. Here you’ll discover challenges that develop you professionally, allowing you to explore a customer-centric culture with a hunger for innovation and improvement.

For a complete list of available career opportunities please contact CeloNova Human Resources at smaldonado@celonova.com.

I acknowledge that I am entering CeloNova’s international website.

Yes ​No